Top 3 Trending Stocks: Ultragenyx Pharmaceutical, Rhythm Pharmaceuticals, and Nurix Therapeutics

Ultragenyx Pharmaceutical (RARE), Rhythm Pharmaceuticals (RYTM), and Nurix Therapeutics (NRIX) are the top three trending stocks among analysts. These biopharmaceutical companies have received a high number of new ratings in the past 72 hours, with analyst consensus being Strong Buy. The average price targets for the stocks suggest potential upside of 168.26%, 9.16%, and 121.31%, respectively.

In recent financial news, three biopharmaceutical companies—Ultragenyx Pharmaceutical (RARE), Rhythm Pharmaceuticals (RYTM), and Nurix Therapeutics (NRIX)—have garnered significant attention from analysts. These companies have received a high number of new ratings in the past 72 hours, with analyst consensus being Strong Buy. The average price targets suggest potential upside of 168.26%, 9.16%, and 121.31%, respectively.

Ultragenyx Pharmaceutical (RARE), currently trading at $41.44, maintained its Buy rating and $80 price target at BofA Securities despite a setback in its Phase 3 Orbit study for setrusumab in osteogenesis imperfecta (OI). The company announced that the study did not reach statistical significance at the second interim analysis, requiring a p-value below 0.01 for success. Despite this, BofA Securities maintains a 60% probability of success for the program, noting that the extended study duration could increase the likelihood of success [1].

Rhythm Pharmaceuticals (RYTM), trading at $89, received an Overweight rating from Morgan Stanley with a price target of $95.00. The stock has surged 35% in the past week, approaching its 52-week high. The firm cited Phase 2 data for bivamelagon in hypothalamic obesity (HO) that showed robust reductions in body mass index (BMI) exceeding 10%, comparable to the range seen with setmelanotide but with an improved profile [2].

Nurix Therapeutics (NRIX), trading at $12.49, had its price target lowered by Oppenheimer from $32.00 to $30.00, but the stock still has an "outperform" rating. The company reported earnings per share of ($0.52) for the quarter, beating the consensus estimate of ($0.79) by $0.27 [3].

These developments reflect ongoing interest and confidence in the growth prospects of these biopharmaceutical companies among analysts and investors. As always, investors should conduct thorough research and consider their risk tolerance before making investment decisions.

References:
[1] https://www.investing.com/news/analyst-ratings/ultragenyx-stock-holds-buy-rating-at-bofa-despite-setrusumab-trial-delay-93CH-4129744
[2] https://www.investing.com/news/analyst-ratings/morgan-stanley-reiterates-overweight-rating-on-rhythm-pharmaceuticals-stock-93CH-4130024
[3] https://www.marketbeat.com/instant-alerts/nurix-therapeutics-nasdaqnrix-price-target-lowered-to-3000-at-oppenheimer-2025-07-10/